Navigation Links
Clinical Interest in BioElectronics' Products Expands to the Wound Care Market
Date:5/9/2012

FREDERICK, Md., May 9, 2012 /PRNewswire/ -- BioElectronics Corporation (OTC-PINK: BIEL), the maker of disposable, inexpensive drug-free topical pain and healing devices, announces the initiation of two independently run clinical trials on venous stasis ulcers. ActiPatch® and RecoveryRx™ use pulsed electromagnetic field therapy to reduce pain and inflammation and promote the healing of injured tissue.

"Clinical research, initiated by facilities independent of the Company, is essential to our future business expansion and revenue growth.  Independent research results will assure consumers, health practitioners and governmental health agencies that our products are both highly effective and extremely safe," said Andrew Whelan, Bioelectronics CEO. "We expect to announce several additional clinical trials in the coming months."

The two clinical trials are double blind, randomized, and placebo controlled.  Both trials are studying the effect of our products on wound healing and the control of wound pain, on venous stasis ulcers, and are currently recruiting patients.  One of these  important research studies is being conducted by Eric Jaakola DPM, FACFAS, at the Diabetic Foot and Wound Center, Denver, Colorado, and the second study is being undertaken by Dr. Rasmussen, Associate Professor Director of Research, Aarhus University Hospital, Aalborg Hospital, Denmark.

"Venous stasis ulcers are the major cause of chronic wounds, occurring in up to 90% of chronic wound cases," commented Ian Rawe, Ph.D., the Director of Clinical Research for BioElectronics.  "Successful completion of these studies will be of great significance, and will help us attract global medical distributors involved in wound care."

"Wound care is a multi-billion dollar international market, in which BioElectronics ActiPatch® and RecoveryRx™ devices can have a major impact.  Additionally, double blind, randomized and placebo controlled trials such as these will help our current distributors to successfully apply for healthcare reimbursement. Reimbursement will significantly expand the use of our RecoveryRx™ device for wound care in many of our current distribution territories throughout the world. We anticipate statistically significant results from both clinical trials by the end of the year," said Dr. Rawe.

About BioElectronics Corporation
BioElectronics is an award winning developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal ailments, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and swelling. For more information, please see www.bielcorp.com.

Contact:  E & E Communications
Paul Knopick
(949) 707-5365


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/11/2019)... ... 11, 2019 , ... Windsor Care Centers (Windsor) across California ... The Society of Corporate Compliance and Ethics & Health Care Compliance Association (SCCE ... 3 through 9, 2019. This is the third year Windsor participated. , Corporate ...
(Date:11/11/2019)... SYOSSET, N.Y. (PRWEB) , ... November 11, 2019 , ... ... with a new telehealth service in place. The program is designed to provide virtual ... devastating Category 5 storm that struck the region in October of 2018 [1]. , ...
(Date:11/11/2019)... ... November 11, 2019 , ... ... facilitate the coordination and implementation of joint projects for the benefit of ... undertakings will empower biomedical professionals to leverage their roles in the research, ...
Breaking Medicine Technology:
(Date:11/19/2019)... ... 18, 2019 , ... “Impact of the Consciousness Energy Healing-based ... named No. 1 International Best Seller and Hot New Release on Amazon in ... and Alternative Medicine. , Kindy’s study investigated the impact of the Biofield ...
(Date:11/16/2019)... , ... November 15, 2019 , ... ... in the United States, access to cannabis via well-managed dispensaries becomes more and ... Wise Business Plans, industry-leading online provider of state-of-the-art, online, custom cannabis business plans ...
(Date:11/15/2019)... , ... November 15, 2019 , ... ... co-builds next-generation cybersecurity and data science companies with nation-state experienced technical teams from ... its second-annual DataTribe Challenge is Code Dx Inc ., based in Northport, ...
(Date:11/14/2019)... ... November 14, 2019 , ... ... linearity and calibration verification kit, specifically targeted for Roche cobas® and Roche ... evaluates a1-Antitrypsin (ATT), Complement C3 (C3), Complement C4 (C4), Immunoglobulin A (IGA), ...
(Date:11/14/2019)... ... 2019 , ... With winter just around the corner, parents want to make sure their children ... might keep little ones warm, during a car ride they can become dangerous, no matter ... snugly in order to ensure maximum safety during a crash or sudden stop. While children ...
Breaking Medicine News(10 mins):